Standard of care treatments in CNS conditions largely target symptoms rather than the underlying cause of the disease. Significant limitations in therapeutic effect and tolerability issues also result in high rates of therapy discontinuation and unmet therapeutic need. New treatments often focus on marginal improvements to the existing symptomatic approaches.  Therefore, new therapeutic classes recently launched, or due to launch in the near future will offer physicians additional treatment options for patients, where outcomes are sub-optimal and tolerability issues still exist. In areas like Parkinson’s and Alzheimer’s the holy grail of true disease modification continues to be a huge challenge pharma aspires to rise to, whilst in MS the last 10yrs has seen some huge strides made and in areas of pain, such as Migraine, drugs with disease-specific indications should revolutionise the existing landscape.

Real-world evidence generated via the CNS Disease Specific Programmes™  provides market insights and understanding, measures disease burden and identifies areas of opportunity for new or existing treatments.

Coronavirus (COVID-19)

As we deal with the current COVID-19 pandemic, we would like to assure you that Adelphi Group are taking every step to ensure the safety and wellbeing of all our staff, families, friends and communities. All staff worldwide are working from home and following individual Government Stay at Home guidelines to do all we can to Protect the Health Services and Save Lives. (UK : https://www.gov.uk/coronavirus) We will continue to exercise ‘Business as Usual’ to ensure our work for all continues. Indeed at the beginning of this month we held an extremely successful all work from home day to test our systems and ability to continue to communicate and deliver for whatever may happen in our world. Little did we know at the time how timely this was to be, and this will be an annual business continuity measure going forward. We would also like to share with you a programme ‘I AM PATIENT‘ produced by one of our Associate Companies, Snow, emphasising the importance of pro-actively following these critically important guidelines and to take personal responsibility to help stop the spread of this deadly virus https://www.youtube.com/watch?v=jZs-F2620CI #iampatient, #stayhome Stay Safe